Full Press Release Details
Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update.
RARE
Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update
Key Takeaway: Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update
Price reaction · baseline $43.3 (2024-05-01 close) · hit after-hours · 1 other RARE headline(s) in the window, move may be shared
day 0 close
-0.2%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+43%
120-day peak, hindsight
Typical move
2.9%
average across 6 past catalysts
Cash runway
~13 mo
Low dilution risk
Lead asset
BPS804
Phase 2 · Hypophosphatasia